Latest Content

Jennifer Wargo, MD, of The University of Texas MD Anderson Cancer Center, has been elected to the 2026 class of Fellows of the American Association for Cancer Research (AACR) Academy.

Christine M. Lovly, MD, PhD, FASCO, discuses acquired resistance in EGFR-mutated NSCLC, including detection and novel approaches to address it.

Multipeptide vaccines in combination with BTK inhibitor–based regimens yielded safety and potent T-cell responses in chronic lymphocytic leukemia.

Susan Scott, MD, Julia Rotow, MD, and Enriqueta Felip, MD, PhD, debate the optimal choice of frontline regimen for EGFR-mutated NSCLC.

OPN-6602 received FDA fast track designation for relapsed/refractory multiple myeloma after at least 4 prior lines of therapy.

A sBLA seeking the approval of zenocutuzumab has been submitted to the FDA, and the agent was added to the NCCN guidelines for NRG1-positive cholangiocarcinoma.

Christian Capitini has been named the next director of the University of Wisconsin Carbone Cancer Center.

During a recent Peer Exchange, breast and lung cancer experts discussed comprehensive strategies for identifying and mitigating the AEs associated with ADCs.

Aaron Gerds, MD, details the rationale behind investigating agents targeting CALR mutations and other novel therapies in myeloproliferative neoplasms.

Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors.

The NCCN updated its 2026 Guidelines for breast cancer screening and diagnosis to include an AI-based risk assessment tool to predict breast cancer risk.

Metronomic treatment approaches could represent therapeutic avenues for patients with TP53-mutated myeloid malignancies.

The CSF-1R–targeting monoclonal antibody emactuzumab met key end points in the phase 3 TANGENT study, setting the stage for a BLA submission.